Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
The Institute Of Zoology Chinese Academy Of Sciences has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 4 pending office actions are being prosecuted by 4 distinct examiners. Furthermore, the workload is spread across 4 distinct art units, indicating a diverse range of biological and pharmaceutical research topics.
PAK, YONG D is the busiest examiner for this portfolio, currently handling 1 pending office action. Since there are 4 distinct examiners for the 4 pending office actions, each examiner is responsible for exactly one matter. The fact that these are in 4 distinct art units suggests that the institute's patent applications are technically distinct enough to be assigned to different specialized groups. This requires the institute to manage 4 independent prosecution paths across 4 different art units. PAK, YONG D is just one of the 4 distinct examiners involved.
For a patent practitioner, this level of distribution means that success in one application may not influence the others. The 4 distinct art units will each apply their own specific technical criteria to the Biotechnology & Pharmaceuticals claims. With 4 pending office actions and 4 distinct examiners, the institute must maintain a highly versatile prosecution strategy. This decentralized structure is common for large research institutions with broad technical portfolios.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAK, YONG D | 1 | 74.6% | +14.3% |
| JADHAO, SAMADHAN JAISING | 1 | 46.9% | +46.2% |
| GROOMS, TIFFANY NICOLE | 1 | 57.8% | +46.3% |
| STAVROU, CONSTANTINA E | 1 | 43.7% | +36.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717976 | ENGINEERED CAS12B EFFECTOR PROTEINS AND METHODS OF USE THEREOF | PAK, YONG D | — |
| 18247058 | APPLICATION OF SUBSTANCE THAT REDUCES THE CONTENT OR ACTIVITY OF KAT7 IN PREVENTING SENESCENCE AND TREATING HEPATIC FIBROSIS | GROOMS, TIFFANY NICOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17761990 | PLURIPOTENT STEM CELL, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | STAVROU, CONSTANTINA E | 13d |
| 18717976 | ENGINEERED CAS12B EFFECTOR PROTEINS AND METHODS OF USE THEREOF | PAK, YONG D | — |
| 18150917 | METHOD FOR IDENTIFYING AND/OR REGULATING SENESCENCE | JADHAO, SAMADHAN JAISING | — |
| 18247058 | APPLICATION OF SUBSTANCE THAT REDUCES THE CONTENT OR ACTIVITY OF KAT7 IN PREVENTING SENESCENCE AND TREATING HEPATIC FIBROSIS | GROOMS, TIFFANY NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| 1672 | 1 |
| 1637 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18717976 | ENGINEERED CAS12B EFFECTOR PROTEINS AND METHODS OF USE THEREOF | PAK, YONG D | 1652 | §103§112 | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18150917 | METHOD FOR IDENTIFYING AND/OR REGULATING SENESCENCE | JADHAO, SAMADHAN JAISING | 1672 | §102§103§112DP | Non-Final OA | — | Pending | Aug 03, 2023 |
| 18247058 | APPLICATION OF SUBSTANCE THAT REDUCES THE CONTENT OR ACTIVITY OF KAT7 IN PREVENTING SENESCENCE AND TREATING HEPATIC FIBROSIS | GROOMS, TIFFANY NICOLE | 1637 | §102§103§112 | Non-Final OA | — | Pending | Mar 28, 2023 |
| 17761990 | PLURIPOTENT STEM CELL, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | STAVROU, CONSTANTINA E | 1632 | §103 | Non-Final OA | 13d | Pending | Mar 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial